Company news
Paradigm Biopharmaceuticals Ltd. news in 2016
Paradigm Biopharmaceuticals Ltd.'s news releases, calls and decks from 2016, newest first.
Paradigms hay fever clinical trial cleared to commence
November 21, 2016
Appendix 4C - September 2016 quarter
October 28, 2016
Paradigms Placement heavily oversubscribed
October 17, 2016
Preclinical study underpins efficacy of Paradigms RhinosulR
September 15, 2016
Paradigm PPS a potential in the treatment of viral arthritis
September 6, 2016
Preliminary Final Report
August 31, 2016
Paradigm PPS nasal spray to treat Allergic Rhinitis
August 19, 2016
Shareholders Update
June 20, 2016
ASX Admission Market Release
June 20, 2016
Paradigm Secures Key US Patent
June 20, 2016
Paradigm Biopharmaceuticals Receives Ethics Approval
June 20, 2016
Paradigm starts Clinical Trial
June 20, 2016
Paradigm initiates second clinical trial site
June 20, 2016
First Participant treated in Paradigms Clinical Trial
June 20, 2016
European Patent Office Grants PAR Key Respiratory Patent
June 20, 2016
Elite Athlete successfully treated with Paradigms Zilosul
June 20, 2016
Decks in 2016
- Shareholder Meeting (November 2016)
Shareholder meeting · 23 slides · Nov 30, 2016
- Non-Deal Roadshow (June 2016)
Roadshow · 22 slides · Jun 20, 2016
- Investor Presentation (March 2016)
Investor deck · 21 slides · Mar 16, 2016